PAVmed Inc (PAVM)
NASDAQ:PAVM
Want to see PAVM full AI Analyst Report?
Earnings Data
Report Date
Aug 18, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.47Last Year’s EPS
-22.2Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized successful capitalization/recapitalization steps, a cleaned cap table, active commercial progress at Lucid and Veris (EHR integration live, VA orders, positive payer engagement), relaunch of the device portfolio with experienced leadership, and measured technical progress on the implantable monitor. At the same time, liquidity remains constrained ($6.5M cash) and a number of positive outcomes depend on milestone-triggered financings (warrants, FDA clearance, Medicare LCD). GAAP results were volatile due to mark-to-market accounting and preferred dividends materially impacted reported earnings; operating expenses have risen ~23% vs. recent quarterly averages. Overall, positives (strategic restructuring, multiple operational milestones, extended Lucid runway, and product development progress) outweigh the near-term financial and milestone risks, but execution and milestone realization will be critical.Company Guidance
Recapitalization and Cleaned Cap Table
Completed a multi-step restructuring: $30.0M Series D preferred offering and a $15.0M senior secured note issued in February; used proceeds to redeem Series C and retire prior convertible debt. Shareholder approval completed late March and the cap table is now simplified (common stock and warrants), positioning the company to pursue growth opportunities and independently financed subsidiaries.
Meaningful Financing Optionality (Warrants and Contingent Proceeds)
Company notes $6.5M cash at March 31 (not including expected contingent proceeds): potential ~$30M from warrant exercise upon a positive EsoGuard LCD and an additional $2.5M from virus-related warrants callable upon FDA clearance — providing material upside to liquidity if triggers occur.
Lucid Diagnostics Progress and Funding
PAVmed remains Lucid's largest shareholder (~15% of common shares; ~25% voting interest). Lucid secured federal supply/pricing and first VA orders, received positive coverage from one laboratory benefit manager, and completed a successful capital raise that management says extends Lucid's runway well into 2027. PAVmed's equity-method investment balance is $36.0M, reflecting a $1.9M mark-to-market increase in the quarter (≈+5.6% q/q).
Veris Commercial Rollout and Technical Progress
Commercial roll-out with Ohio State University is underway: EHR integration is live, initial clinical departments are expanding per rollout plan, feedback is positive, and the registry is trending toward the goal of 1,000 patients in the first year. Development toward the implantable physiologic monitor is progressing, with a target for plan submission/permitting by year-end and notable progress optimizing battery life to achieve a full two-year target.
Relaunch of Medical Device Portfolio with Dedicated Leadership
Company hired an experienced medical-device executive to lead the relaunch of its device portfolio (bringing previously shelved assets back into active development and licensing). This leader is focused on advancing multiple device opportunities (including imaging tech licensed from Duke) and raising capital for individual initiatives while leveraging PAVmed's shared-services model.
Recurring Pro Forma Revenue Sources
On a pro forma illustrative basis, combined device/virus-related revenue plus Lucid management fee income totals more than $3.0M per quarter, demonstrating diversified income streams that can help offset operating expenses (noting this presentation was illustrative for internal alignment purposes).
PAVM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PAVM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2026 | $6.45 | $6.53 | +1.24% |
Nov 13, 2025 | $11.60 | $10.61 | -8.53% |
Nov 13, 2025 | $11.60 | $10.61 | -8.53% |
Aug 14, 2025 | $13.80 | $13.69 | -0.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PAVmed Inc (PAVM) report earnings?
PAVmed Inc (PAVM) is schdueled to report earning on Aug 18, 2026, Before Open (Confirmed).
What is PAVmed Inc (PAVM) earnings time?
PAVmed Inc (PAVM) earnings time is at Aug 18, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PAVM EPS forecast?
PAVM EPS forecast for the fiscal quarter 2026 (Q2) is -0.47.